What is claimed is:
1. A method of treatment of benign prostatic hyperplasia comprising the steps of:
(a) orally administering an initial dosage of about 40 mg of 13-cis-retinoic acid daily for an initial treatment period from about ten days to about twenty days, and
(b) thereafter orally administering a sustaining dosage of about 40 mg of 13-cis-retinoic acid about every five to seven days in a sustaining period.
2. The method of claim 1 wherein said sustaining period is about one year.
3. The method of claim 1 wherein said initial treatment period is about fourteen days.
4. The method of claim 1 wherein said 13-cis-retinoic acid is in a form selected from the group consisting of powder, pill, capsule, tablet, and liquid.
5. The method of claim 4 wherein said liquids comprise 13-cis-retinoic acid in a pharmaceutical media selected from the group consisting of water, glycol, oil, alcohol, and syrup.
6. A method of reduction of a level of a prostate specific antigen (PSA) of benign prostate conditions comprising the steps of:
(a) orally administering an initial dosage of about 40 mg of 13-cis-retinoic acid daily for an initial treatment period from about ten days to about twenty days, and
(b) thereafter orally administering a sustaining dosage of about 40 mg of 13-cis-retinoic acid about every five to seven days in a sustaining period.
7. The method of claim 6 wherein said sustaining period is about one year.
8. The method of claim 6 wherein said initial treatment period is about fourteen days.
9. The method of claim 6 wherein said 13-cis-retinoic acid is in a form selected from the group consisting of powder, pill, capsule, tablet, and liquid.
10. The method of claim 9 wherein said liquids comprise 13-cis-retinoic acid in a pharmaceutical media selected from the group consisting of water, glycol, oil, alcohol, and syrup.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1-30. (canceled)
31. A plate glass which comprises, as represented by mole percentage based on oxides, from 62 to 68% of SiO2, from 6 to 12% of Al2O3, from 7 to 13% of MgO, from 9 to 15% of Na2O, from 0 to 7% of K2O, and from 0 to 1% of CaO, wherein the difference obtained by subtracting the content of Al2O3 from the total content of Na2O and K2O is less than 10%, and ZrO2 is contained in an amount of at most 0.8%.
32. The plate glass according to claim 31, wherein the content of CaO is from 0 to 0.5%.
33. The plate glass according to claim 31, wherein ZrO2 is contained in an amount of at most 0.5%.
34. The plate glass according to claim 31 or 32, wherein the content of Na2O is from 9 to 12.5%.
35. The plate glass according to claim 31 or 32, wherein the content of Na2O is from 12 to 15%.
36. The plate glass according to claim 31 or 32, which contains no B2O3.
37. The plate glass according to claim 31 or 32, wherein the content of Al2O3 is from 7 to 10%
38. The plate glass according to claim 31 or 32, wherein the total content of CaO, SrO and BaO is at most 1%.
39. The plate glass according to claim 31 or 32, wherein the total content of SiO2 and Al2O3 is more than 72% and at most 76%.
40. The plate glass according to claim 31 or 32, wherein the content of MgO is from 8 to 11%.
41. The plate glass according to claim 31 or 32, wherein the content of SiO2 is from 63 to 65%.